Overview

Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

Status:
Completed
Trial end date:
2019-05-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2A study designed to evaluate the safety and tolerability of increased repeated doses of LYC-55716 in subjects with locally advanced or metastatic solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Lycera Corp.